Morepen Labs Q2/H1 FY27: Record Revenue, EBITDA & PAT Growth
Morepen Laboratories reported record revenue, EBITDA, and PAT for Q2 and H1 FY27. Q2 revenue was ₹755 Cr, with EBITDA up 273% and PAT up 117%. H1 revenue reached ₹1330 Cr, with EBITDA up 177% and PAT up 243%. CDMO revenue was ₹253 Cr in Q2, and export revenue grew 122% to ₹654 Cr.
The announcement details significant year-on-year growth in revenue, EBITDA, and PAT, along with strategic business segment performance and capacity expansions, which are material events for investors.
The company has reported record revenues, EBITDA, and PAT for both Q2 and H1 FY27, indicating strong financial performance and growth across its key business segments.
Morepen Laboratories Limited has announced its financial performance for the second quarter (Q2) and first half (H1) of FY27, reporting a second consecutive quarter of record revenue and earnings.
For Q2 FY27, the company achieved a revenue of ₹755 crore, marking a significant year-on-year (YoY) increase. EBITDA grew by an impressive 273% YoY to ₹132 crore, with EBITDA margins expanding by 897 basis points. Profit After Tax (PAT) also saw a substantial YoY jump of 117% to ₹89 crore.
The performance in H1 FY27 continued this positive trend, with revenue reaching ₹1330 crore. EBITDA for the half-year surged by 177% YoY to ₹220 crore, and PAT increased by 243% YoY to ₹145 crore. The company highlighted improvements in Return on Capital Employed (ROCE) and Return on Equity (ROE), along with a reduction in receivables and debt-to-equity ratio.
The CDMO (Contract Development and Manufacturing Organization) business showed strong growth, with Q2 CDMO revenue reaching ₹253 crore, now constituting 52% of the combined API and CDMO revenue. API revenue in H1 FY27 was ₹1330 crore, with new molecules contributing 25% to this segment. Export revenue for H1 FY27 stood at ₹654 crore, a 122% YoY increase, now representing approximately 50% of the company's total sales revenue.
The medical devices segment also performed well, with Q2 revenue at ₹208 crore (up 65% YoY) and H1 revenue at ₹399 crore (up 39% YoY). The company emphasized its diversified platform, focusing on higher-value products, global expansion, and capacity enhancement, with manufacturing capacity increasing from 614 KL to 800 KL.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.